Wall Street Zen Downgrades Niagen Bioscience (NASDAQ:NAGE) to Hold

Niagen Bioscience (NASDAQ:NAGE) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity Group restated a “buy” rating and issued a $13.00 price objective on shares of Niagen Bioscience in a report on Tuesday, March 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Niagen Bioscience Stock Up 4.2%

NAGE opened at $4.93 on Friday. The company has a market capitalization of $394.79 million, a price-to-earnings ratio of 24.65 and a beta of 2.23. The firm has a 50-day moving average price of $4.78 and a 200-day moving average price of $5.97. Niagen Bioscience has a twelve month low of $4.16 and a twelve month high of $14.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NAGE. CWM LLC purchased a new position in shares of Niagen Bioscience in the third quarter valued at $246,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Niagen Bioscience in the third quarter valued at $144,000. Financial Consulate Inc. bought a new stake in Niagen Bioscience in the third quarter worth $33,000. D.A. Davidson & CO. bought a new stake in Niagen Bioscience in the third quarter worth $251,000. Finally, North Star Investment Management Corp. bought a new stake in Niagen Bioscience in the third quarter worth $47,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.